Key components of chemotherapy for thymic malignancies: a systematic review and pooled analysis for anthracycline-, carboplatin- or cisplatin-based chemotherapy

Journal of Cancer Research and Clinical Oncology

Volumn 141, Issue 2, 2015, Pages 323-331

  Okuma, Yusuke ^a,b   Saito, Makoto ^a   Hosomi, Yukio ^a   Sakuyama, Toshikazu ^b   Okamura, Tatsuru ^a  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Chemotherapy; Rare cancer; Thymic carcinoma; Thymic malignancies; Thymoma

Indexed keywords

AMRUBICIN; ANTHRACYCLINE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; IRINOTECAN; METHYLPREDNISOLONE; PACLITAXEL; PLATINUM DERIVATIVE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; HUMAN; INFORMATION RETRIEVAL; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; THYMOMA; THYMUS CANCER; TREATMENT RESPONSE; CLINICAL TRIAL (TOPIC); PROGNOSIS; THYMUS NEOPLASMS;

ANTHRACYCLINES; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CISPLATIN; CLINICAL TRIALS AS TOPIC; HUMANS; PROGNOSIS; THYMUS NEOPLASMS;

EID: 84921031614     PISSN: 01715216     EISSN: 14321335     Source Type: Journal    
DOI: 10.1007/s00432-014-1800-6     Document Type: Article

References (44)

1. Agatsuma T, Koizumi T, Kanda S, Ito M, Urushihata K, Yamamoto H, Hanaoka M, Kubo K (2011) Combination chemotherapy with doxorubicin, vincristine, cyclophosphamide, and platinum compounds for advanced thymic carcinoma. J Thorac Oncol 6(12):2130–2134
2. Anderson JR, Cain KC, Gelber RD (1983) Analysis of survival by tumor response. J Clin Oncol 1(11):710–719
3. Bernatz PE, Harrison EG, Clagett OT (1961) Thymoma: a clinicopathologic study. J Thorac Cardiovasc Surg 42:424–444
4. Berruti A, Borasio P, Gerbino A, Gorzegno G, Moschini T, Tampellini M, Ardissone F, Brizzi MP, Dolcetti A, Dogliotti L (1999) Primary chemotherapy with adriamycin, cisplatin, vincristine and cyclophosphamide in locally advanced thymomas: a single institution experience. Br J Cancer 81(5):841–845
5. de Jong WK, Blaauwgeers JL, Schaapveld M, Timens W, Klinkenberg TJ, Groen HJ (2008) Thymic epithelial tumours: a population-based study of the incidence, diagnostic procedures and therapy. Eur J Cancer 44(1):123–130
6. Detterbeck FC, Asamura H, Crowley J, Falkson C, Giaccone G, Giroux D, Huang J, Kim J, Kondo K, Lucchi M, Marino M, Marom EM, Nicholson A, Okumura M, Ruffini E, van Schil P, Stratton K, Staging, Prognostic Factors C, Members of the Advisory B, Participating Institutions of the Thymic D (2013) The IASLC/ITMIG thymic malignancies staging project: development of a stage classification for thymic malignancies. J Thorac Oncol 8(12):1467–1473
7. Engel P, Marx A, Muller-Hermelink HK (1999) Thymic tumours in Denmark. A retrospective study of 213 cases from 1970-1993. Pathol Res Pract 195(8):565–570
8. Engels EA (2010) Epidemiology of thymoma and associated malignancies. J Thorac Oncol 5(10 Suppl 4):S260–S265
9. Fornasiero A, Daniele O, Ghiotto C, Piazza M, Fiore-Donati L, Calabro F, Rea F, Fiorentino MV (1991) Chemotherapy for invasive thymoma. A 13-year experience. Cancer 68(1):30–33
10. Furugen M, Sekine I, Tsuta K, Horinouchi H, Nokihara H, Yamamoto N, Kubota K, Tamura T (2011) Combination chemotherapy with carboplatin and paclitaxel for advanced thymic cancer. Jpn J Clin Oncol 41(8):1013–1016
11. Gao L, Wang C, Fang W, Zhang J, Lv C, Fu S (2013) Outcome of multimodality treatment for 188 cases of type b3 thymoma. J Thorac Oncol 8(10):1329–1334
12. Giaccone G, Ardizzoni A, Kirkpatrick A, Clerico M, Sahmoud T, van Zandwijk N (1996) Cisplatin and etoposide combination chemotherapy for locally advanced or metastatic thymoma. A phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 14(3):814–820
13. Girard N, Lal R, Wakelee H, Riely GJ, Loehrer PJ (2011) Chemotherapy definitions and policies for thymic malignancies. J Thorac Oncol 6(7 Suppl 3):S1749–S1755
14. Grassin F, Paleiron N, Andre M, Caliandro R, Bretel JJ, Terrier P, Margery J, Le Chevalier T, Ruffie P (2011) Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma. A French experience. J Thorac Oncol 5(6):893–897
15. Huang J, Detterbeck FC, Wang Z, Loehrer PJ Sr (2010) Standard outcome measures for thymic malignancies. J Thorac Oncol 5(12):2017–2023
16. Igawa S, Murakami H, Takahashi T, Nakamura Y, Tsuya A, Naito T, Kaira K, Ono A, Shukuya T, Tamiya A, Endo M, Yamamoto N (2010) Efficacy of chemotherapy with carboplatin and paclitaxel for unresectable thymic carcinoma. Lung Cancer 67(2):194–197
17. Kawashima Y, Inoue A, Sugawara S, Harada M, Kobayashi K, Kozuki T, Kuyama S, Sakakibara T, Maemondo M, Asahina H, Hisamoto A, Nakagawa T, Nukiwa T (2013) Phase II study of amrubicin (AMR) and carboplatin (CBDCA) for invasive thymoma (IT) and thymic carcinoma (TC): NJLCG0803. ASCO Meeting Abstracts 31(15_suppl):7530
18. Kim ES, Putnam JB, Komaki R, Walsh GL, Ro JY, Shin HJ, Truong M, Moon H, Swisher SG, Fossella FV, Khuri FR, Hong WK, Shin DM (2004) Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer 44(3):369–379
19. Kunitoh H, Tamura T, Shibata T, Nakagawa K, Takeda K, Nishiwaki Y, Osaki Y, Noda K, Yokoyama A, Saijo N, Jcog Lung Cancer Study Group TJ (2009) A phase-II trial of dose-dense chemotherapy in patients with disseminated thymoma: report of a Japan Clinical Oncology Group trial (JCOG 9605). Br J Cancer 101(9):1549–1554
20. Lauriola L, Erlandson RA, Rosai J (1998) Neuroendocrine differentiation is a common feature of thymic carcinoma. Am J Surg Pathol 22(9):1059–1066
21. Lemma GL, Lee JW, Aisner SC, Langer CJ, Tester WJ, Johnson DH, Loehrer PJ Sr (2011) Phase II study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma. J Clin Oncol 29(15):2060–2065
22. Levine GD, Rosai J (1978) Thymic hyperplasia and neoplasia: a review of current concepts. Hum Pathol 9(5):495–515
23. Loehrer PJ Sr, Kim K, Aisner SC, Livingston R, Einhorn LH, Johnson D, Blum R (1994) Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group. J Clin Oncol 12(6):1164–1168
24. Loehrer PJ Sr, Chen M, Kim K, Aisner SC, Einhorn LH, Livingston R, Johnson D (1997) Cisplatin, doxorubicin, and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: an intergroup trial. J Clin Oncol 15(9):3093–3099
25. Loehrer PJ Sr, Jiroutek M, Aisner S, Aisner J, Green M, Thomas CR Jr, Livingston R, Johnson DH (2001) Combined etoposide, ifosfamide, and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma: an intergroup trial. Cancer 91(11):2010–2015
26. Lucchi M, Melfi F, Dini P, Basolo F, Viti A, Givigliano F, Angeletti CA, Mussi A (2006) Neoadjuvant chemotherapy for stage III and IVA thymomas: a single-institution experience with a long follow-up. J Thorac Oncol 1(4):308–313
27. Masaoka A (2010) Staging system of thymoma. J Thorac Oncol 5(10 Suppl 4):S304–S312
28. Monica V, Familiari U, Chiusa L, Rossi G, Novero D, Busso S, Ruffini E, Ardissone F, Scagliotti GV, Papotti M (2013) Messenger RNA and protein expression of thymidylate synthase and DNA repair genes in thymic tumors. Lung Cancer 79(3):228–235
29. Muller-Hermelink HK, Marino M, Palestro G (1986) Pathology of thymic epithelial tumors. Curr Top Pathol 75:207–268
30. Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, Fukuoka M, Mori K, Watanabe K, Tamura T, Yamamoto S, Saijo N (2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346(2):85–91
31. Noguchi T, Hanada M, Yamaoka T (2005) Development of a novel anti-tumor drug ‘amrubicin’, a completely synthetic anthracycline. SUMITOMO KAGAKU 2005-II:1–11
32. Ohe Y, Ohashi Y, Kubota K, Tamura T, Nakagawa K, Negoro S, Nishiwaki Y, Saijo N, Ariyoshi Y, Fukuoka M (2007) Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 18(2):317–323
33. Okuma Y, Hosomi Y, Takagi Y, Iguchi M, Okamura T, Shibuya M (2011) Cisplatin and irinotecan combination chemotherapy for advanced thymic carcinoma: evaluation of efficacy and toxicity. Lung Cancer 74(3):492–496
34. Park S, Ahn MJ, Ahn JS, Sun JM, Shim YM, Kim J, Choi YS, Kim K, Shin S, Ahn Y, Kwon OJ, Kim H, Lee SJ, Chang WJ, Park K (2013) A prospective phase II trial of induction chemotherapy with docetaxel/cisplatin for Masaoka stage III/IV thymic epithelial tumors. J Thorac Oncol 8(7):959–966
35. Rea F, Sartori F, Loy M, Calabro F, Fornasiero A, Daniele O, Altavilla G (1993) Chemotherapy and operation for invasive thymoma. J Thorac Cardiovasc Surg 106(3):543–549
36. Rosai J (1999) Histological typing of tumours of the thymus. In: World Health Organization International Histological Classification of Tumours. Springer, Berlin
37. Schmitt J, Loehrer PJ Sr (2010) The role of chemotherapy in advanced thymoma. J Thorac Oncol 5(10 Suppl 4):S357–S360
38. Sugiura H, Fujiwara Y, Ando M, Kawai A, Ogose A, Ozaki T, Yokoyama R, Hiruma T, Ishii T, Morioka H, Mugishima H (2010) Multicenter phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma. J Orthop Sci 15(5):654–660
39. Takeda K, Hirai F, Yamanaka T, Taguchi K, Daga H, Shimizu J, Kogure Y, Kimura T, Tanaka K, Iwamoto Y, Ono A, Sasaki H, Fukuoka J, Nishiyama K, Seto T, Ichinose Y, Nakagawa K, Nakanishi Y, West Japan Oncology Group (2013) A multicenter prospective study of carboplatin and paclitaxel for advanced thymic carcinoma: West Japan Oncology Group 4207L. ASCO Meeting Abstracts 31(15_suppl):7529
40. Travis W, Brambilla W, Müller-Hermelink H, Harris C (2004) World Health Organization classification of tumors. Pathology and genetics of tumors of the lung, pleura, thymus and heart. Chapter 3. IARC press, Lyon
41. Weksler B, Dhupar R, Parikh V, Nason KS, Pennathur A, Ferson PF (2013) Thymic carcinoma: a multivariate analysis of factors predictive of survival in 290 patients. Ann Thorac Surg 95(1):299–303
42. Yoh K, Goto K, Ishii G, Niho S, Ohmatsu H, Kubota K, Kakinuma R, Nagai K, Suga M, Nishiwaki Y (2003) Weekly chemotherapy with cisplatin, vincristine, doxorubicin, and etoposide is an effective treatment for advanced thymic carcinoma. Cancer 98(5):926–931
43. Yokoi K, Matsuguma H, Nakahara R, Kondo T, Kamiyama Y, Mori K, Miyazawa N (2007) Multidisciplinary treatment for advanced invasive thymoma with cisplatin, doxorubicin, and methylprednisolone. J Thorac Oncol 2(1):73–78
44. Zucali PA, Di Tommaso L, Petrini I, Battista S, Lee HS, Merino M, Lorenzi E, Voulaz E, De Vincenzo F, Simonelli M, Roncalli M, Giordano L, Alloisio M, Santoro A, Giaccone G (2013) Reproducibility of the WHO classification of thymomas: practical implications. Lung Cancer 79(3):236–241